Milrinone During Living Donor Hepatectomy

Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00966745

Enrollment

Registered

2009-08-27

Start date

2008-01-31

Completion date

2008-12-31

Last updated

2009-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatectomy

Keywords

surgical field condition

Brief summary

Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.

Interventions

DRUGmilrinone

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 55 Years

Healthy volunteers

Inclusion criteria

* Living liver donors

Exclusion criteria

* Donors with concurrent cardiac, pulmonary, and urologic disease * Hepatectomy performed laparoscopically

Design outcomes

Primary

Measure	Time frame
condition of surgical field	intraoperative period (from the start of surgery to end of living donor hepatectomy)

Secondary

Measure	Time frame
the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively	intraoperative period (from the start of surgery to end of living donor hepatectomy)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026